REDWOOD CITY, CA / ACCESSWIRE / October 26, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2023.
Third Quarter and Recent Highlights
"With full commercial launch of our Tigereye ST CTO-crossing catheter and limited launch of our new Pantheris LV image-guided atherectomy system in the third quarter, exciting new clinical outcomes data for our Pantheris SV below-the-knee atherectomy device, and the outstanding performance and increased mobility of our Lightbox 3 imaging console launched last year, we have built the most advanced peripheral products portfolio in the industry," commented Jeff Soinski, Avinger's President and CEO.
"To support the launch of our new product offerings and drive meaningful revenue growth in 2024, we are commencing an expansion of our sales team with plans to increase the size of our direct sales force by more than 25% in the fourth quarter. I am thrilled to have Phil Preuss lead these efforts in his new role as Chief Commercial Officer. Phil brings over 15 years of direct industry experience to this expanded role and has been deeply involved in the commercial launch and development of our advanced product portfolio in his prior position as Chief Marketing Officer.
"We continue to make excellent progress on the development of our first coronary product application, including the successful completion of animal studies and cadaver heart studies in an innovative coronary test model at a leading clinical institution. We are excited about the results we are seeing as we continue to advance our lead design candidate and anticipate filing an IDE application with the FDA by mid-2024 to allow for the initiation of a clinical study following approval. Our first entry into the coronary space is designed to provide superior, simplified, and more predictable clinical outcomes while crossing chronic total occlusions in the coronary arteries, and we are excited about the prospect of extending our proprietary image-guided approach to this large and underserved market with well-established reimbursement."
Third Quarter 2023 Financial Results
Total revenue was $1.8 million for the third quarter of 2023, compared with $2.0 million in the second quarter of 2023 and $2.3 million in the third quarter of 2022 . The change in sales revenue primarily reflected a decrease in sales headcount, while sales productivity for existing team members remained consistent with the prior quarter. The company has hired two new clinical specialists in October as a first step in expanding our clinical support capabilities with the hiring of additional sales and clinical support personnel planned for the fourth quarter.
Gross margin for the third quarter of 2023 was 21%, compared with 30% in the second quarter of 2023 and 35% in the third quarter of 2022. The change in gross margin primarily reflected lower manufacturing volume over fixed costs in the third quarter. Operating expenses for the third quarter of 2023 were $4.4 million, up slightly from $4.3 million in the second quarter of 2023 and down from $4.5 million in the third quarter of 2022 as the company maintains an efficient operating expense structure.
Net loss and comprehensive loss for the third quarter of 2023 was $4.5 million, compared with $4.2 million in the second quarter of 2023 and $4.1 million in the third quarter of 2022.
Adjusted EBITDA, as defined under non-GAAP financial measures in this press release, was a loss of $3.7 million, up slightly from a loss of $3.4 million in the second quarter of 2023 and a loss of $3.6 million in the third quarter of 2022. For more information regarding non-GAAP financial measures discussed in this press release, please see "Non-GAAP Financial Measures" below, as well as the reconciliation of non-GAAP measures to the nearest GAAP measure, provided in the tables below.
Cash and cash equivalents totaled $8.7 million as of September 30, 2023.
Conference Call
Avinger will hold a conference call today, October 26, 2023, at 4:30pm ET to discuss its third quarter 2023 financial results.
To listen to a live webcast, please visit http://www.avinger.com and select Investor Relations. To join the call by telephone, please dial +1-973-528-0011 and use passcode 782086. A webcast replay of the call will be available on Avinger's website following completion of the call at www.avinger.com.
About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and Tigereye ® family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.
Follow Avinger on Twitter and Facebook.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our future performance, our expected hiring of additional sales and clinical support personnel, patient and physician benefits of our products , the impacts of our products on the treatment of vascular disease, our ability to successfully develop new products, including products relating to the treatment of coronary artery disease (CAD), the timing of the development of new products, the impact of products developed for the treatment of CAD on our business and results of operations, the potential success of our coronary product application, and our expectation regarding the timing relating to our goal of filing an IDE application relating to a clinical study, and the timing regarding the initiation of a clinical study. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include our dependency on a limited number of products; the resource requirements related to Pantheris, Tigereye and our Lightbox imaging console; the outcome of clinical trial results; the adoption of our products by physicians; our ability to obtain regulatory approvals for our products; as well as the other risks described in the section entitled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2023, as amended, and Quarterly Reports on Form 10-Q. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Avinger disclaims any obligation to update these forward- looking statements.
Non-GAAP Financial Measures
Avinger has provided in this press release financial information that has not been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The Company uses these non-GAAP financial measures internally in analyzing its financial results and believes that the use of these non-GAAP financial measures is useful to investors as an additional tool to evaluate ongoing operating results and trends and in comparing the Company's financial results with other companies in its industry, many of which present similar non-GAAP financial measures.
The presentation of these non-GAAP financial measures should not be considered in isolation or as a substitute for comparable GAAP financial measures, and should be read only in conjunction with the Company's financial statements prepared in accordance with GAAP. A reconciliation of the Company's non-GAAP financial measures to their most directly comparable GAAP measures has been provided in the financial statement tables included in this press release, and investors are encouraged to review these reconciliations.
Adjusted EBITDA. Avinger defines Adjusted EBITDA as net loss and comprehensive loss plus interest expense, net, plus other income, net, plus stock-based compensation expense plus certain inventory charges plus certain depreciation and amortization expense. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Furthermore, these non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP, and the components that Avinger excludes in its calculation of non-GAAP financial measures may differ from the components that its peer companies exclude when they report their non-GAAP results of operations. Avinger compensates for these limitations by providing specific information regarding the GAAP amounts excluded from these non-GAAP financial measures. In the future, the Company may also exclude other non-recurring expenses and other expenses that do not reflect the Company's core business operating results.
Investor Contact:
Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
This email address is being protected from spambots. You need JavaScript enabled to view it.
Public Relations Contact:
Phil Preuss
Chief Commercial Officer
Avinger, Inc.
(650) 241-7942
This email address is being protected from spambots. You need JavaScript enabled to view it.
Statements of Operations and Comprehensive Loss
(in thousands, except per share amounts) (unaudited)
| For the Three Months Ended | Nine Months Ended | |||||||||||||||||||
| September 30, | June 30, | September 30, | September 30, | September 30, | ||||||||||||||||
| 2023 | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||
Revenues | $ | 1,817 | $ | 2,041 | $ | 2,252 | $ | 5,746 | $ | 6,272 | ||||||||||
Cost of revenues | 1,429 | 1,436 | 1,462 | 4,117 | 4,301 | |||||||||||||||
Gross profit | 388 | 605 | 790 | 1,629 | 1,971 | |||||||||||||||
Operating expenses | ||||||||||||||||||||
Research and development | 1,044 | 988 | 1,086 | 3,388 | 3,244 | |||||||||||||||
Selling, general and administrative | 3,377 | 3,346 | 3,384 | 10,261 | 10,862 | |||||||||||||||
Total operating expenses | 4,421 | 4,334 | 4,470 | 13,649 | 14,106 | |||||||||||||||
Loss from operations | (4,033 | ) | (3,729 | ) | (3,680 | ) | (12,020 | ) | (12,135 | ) | ||||||||||
Interest expense, net | (455 | ) | (445 | ) | (407 | ) | (1,292 | ) | (1,286 | ) | ||||||||||
Other income (expense), net | 12 | (2 | ) | - | 16 | (20 | ) | |||||||||||||
Net loss and comprehensive loss | (4,476 | ) | (4,176 | ) | (4,087 | ) | (13,296 | ) | (13,441 | ) | ||||||||||
Waiver (accretion) of preferred stock dividends | 2,436 | (1,218 | ) | (1,127 | ) | - | (3,381 | ) | ||||||||||||
Deemed dividend arising from beneficial conversion feature of convertible preferred stock | - | - | - | - | (5,111 | ) | ||||||||||||||
Net loss applicable to common stockholders | $ | (2,040 | ) | $ | (5,394 | ) | $ | (5,214 | ) | $ | (13,296 | ) | $ | (21,933 | ) | |||||
Net loss per share attributable to common stockholders | ||||||||||||||||||||
basic and diluted | $ | (2.92 | ) | $ | (8.86 | ) | $ | (11.51 | ) | $ | (21.48 | ) | $ | (56.67 | ) | |||||
Weighted average common shares used to compute | ||||||||||||||||||||
net loss per share, basic and diluted | 698 | 609 | 453 | 619 | 387 | |||||||||||||||
Reconciliation of Adjusted EBITDA to Net Loss and Comprehensive Loss
(in thousands) (unaudited)
| For the Three Months Ended | Nine Months Ended | |||||||||||||||||||
| September 30, | June 30, | September 30, | September 30, | September 30, | ||||||||||||||||
| 2023 | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||
Net loss and comprehensive loss | $ | (4,476 | ) | $ | (4,176 | ) | $ | (4,087 | ) | $ | (13,296 | ) | $ | (13,441 | ) | |||||
Add: Interest expense, net | 455 | 445 | 407 | 1,292 | 1,286 | |||||||||||||||
Add: Other income (expense), net (1) | (12 | ) | 2 | - | (16 | ) | 20 | |||||||||||||
Add: Stock-based compensation | 219 | 239 | 39 | 703 | 127 | |||||||||||||||
Add: Certain depreciation and amortization charges | 74 | 68 | 54 | 214 | 133 | |||||||||||||||
Adjusted EBITDA | $ | (3,740 | ) | $ | (3,422 | ) | $ | (3,587 | ) | $ | (11,103 | ) | $ | (11,875 | ) | |||||
(1) Other income(expense), net primarily represents other miscellaneous income and expenses. Since these charges are non-operational, unusual or infrequent in nature, they are excluded accordingly.
Balance Sheet
(in thousands, except per share amounts) (unaudited)
| September 30, | December 31, | |||||||
Assets | 2023 | 2022 | ||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 8,725 | $ | 14,603 | ||||
Accounts receivable, net of allowance for doubtful accounts | ||||||||
of $24 at September 30, 2023 and $73 at December 31, 2022 | 828 | 1,057 | ||||||
Inventories | 5,580 | 4,965 | ||||||
Prepaid expenses and other current assets | 550 | 362 | ||||||
Total current assets | 15,683 | 20,987 | ||||||
Right of use asset | 1,384 | 2,194 | ||||||
Property and equipment, net | 528 | 702 | ||||||
Other assets | 249 | 312 | ||||||
Total assets | $ | 17,844 | $ | 24,195 | ||||
Liabilities and stockholders' (deficit) equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 549 | $ | 631 | ||||
Accrued compensation | 1,947 | 1,401 | ||||||
Accrued expenses and other current liabilities | 897 | 657 | ||||||
Leasehold liability, current portion | 1,179 | 1,092 | ||||||
Borrowings | 13,794 | 14,165 | ||||||
Total current liabilities | 18,366 | 17,946 | ||||||
Leasehold liability, long-term portion | 205 | 1,102 | ||||||
Other long-term liabilities | 627 | 1,001 | ||||||
Total liabilities | 19,198 | 20,049 | ||||||
Stockholders' (deficit) equity: | ||||||||
Convertible preferred stock, par value $0.001 | - | - | ||||||
Common stock, par value $0.001 | 1 | 8 | ||||||
Additional paid-in capital | 414,317 | 406,514 | ||||||
Accumulated deficit | (415,672 | ) | (402,376 | ) | ||||
Total stockholders' (deficit) equity | (1,354 | ) | 4,146 | |||||
Total liabilities and stockholders' (deficit) equity | $ | 17,844 | $ | 24,195 | ||||
| Last Trade: | US$0.56 |
| Daily Change: | -0.008 -1.40 |
| Daily Volume: | 229,152 |
| Market Cap: | US$1.800M |
November 07, 2024 October 24, 2024 September 18, 2024 August 20, 2024 August 08, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
